MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition

Abstract

Context: Constitutively active KIT tyrosine kinase harboring the D816V mutation is the major driver of systemic mastocytosis (SM) pathogenesis. We have previously reported that the loss of function of SETD2 histone methyltransferase due to reduced protein stability is a common cooperating event in advanced SM (advSM). Objective: To dissect the mechanisms of action of midostaurin in advSM and to explore the potential of SETD2 as a marker of response to therapy. Materials: The mast cell (MC) leukemia cell line HMC-1 (negative for SETD2) and primary neoplastic MCs from 10 advSM patients, collected at regular time points during midostaurin treatment. Results: This study started from our preliminary observations indicating that aurora kinase A (AKA) is overexpressed and hyperactivated in advSM and is implicated in SETD2 proteasomal degradation. The new gold standard of therapy in advSM is midostaurin, which targets KIT andseveral other kinases, including AKA. We, thus, investigated whether midostaurin treatment may result in efficient AKA inhibition and subsequent SETD2 rescue. To this purpose, the HMC-1 cell line was treated with 5 µM midostaurin for 24 h, and phospho-AKA (T288), SETD2, and H3K36me3 (surrogate marker of SETD2 activity) were evaluated by WB. Midostaurin reduced AKA phosphorylation by 60%, partially restoring SETD2 expression and activity. We next wondered whether the same happens in patients treated with midostaurin. We, thus, collected and performed WB analysis on neoplastic mast cells from advSM patients before and during midostaurin treatment. We found that midostaurin may target AKA and rescue SETD2 expression and function in vivo and that SETD2/H3K36me3 rescue correlates with the clinical response to midostaurin and the reduction of KIT D816V allele burden, as assessed by digital PCR at 3, 6, and 12 months. In 8 patients who responded to midostaurin, SETD2/H3K36me3 rescue was detected by WB as early as 3 months after treatment onset, whereas 2 refractory patients did not show any increase in SETD2/H3K36me3 and maintained an unaltered KIT allele burden. Conclusions: Midostaurin treatment induces AKA partial dephosphorylation and consequent rescue of SETD2 expression and function in vitro and in vivo SETD2/H3K36me3 may serve as a biomarker of response to midostaurin. Supported by AIRC project 23001